Proteins, I.e., More Than 100 Amino Acid Residues Patents (Class 530/350)
  • Patent number: 10995155
    Abstract: The present disclosure provides a composite of (a) oxidized cellulose comprising at least one carboxyl and (b) at least one component selected from a diamine, a diol, or mixture thereof. This disclosure further relates to methods of making such composite materials and suitable uses thereof, including in fibers, fabrics, textiles, films, fillers, packaging materials, plastics, etc.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: May 4, 2021
    Assignee: GP CELLULOSE GMBH
    Inventors: Arthur J. Nonni, Charles E. Courchene, Christopher M. Slone, Blair R. Carter, Anna L. Wells, James M. Keough
  • Patent number: 10980826
    Abstract: The present application provides a pharmaceutical composition for treating and/or preventing a cancer comprising, as an active ingredient, a polynucleotide derived from miRNA associated with the cancer, a combination drug of the pharmaceutical composition and another antitumor agent, and a method for treating or preventing a cancer in a subject having the cancer using the pharmaceutical composition or the combination drug.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: April 20, 2021
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Atsuko Miyano, Hiroko Sudo, Aiko Takayama, Taiga Arai
  • Patent number: 10981959
    Abstract: Compositions comprising a mixture of proteins derived from MaSP, nucleic acids encoding same and method for the preparation of synthetic dragline spider silk are provided. The compositions of the invention comprise a mixture of proteins of differing molecular weight, wherein each protein of said mixture comprises, independently, multiple repeats of a repetitive region of a MaSP (major ampullate spidroin) protein or a functional homolog, variant, derivative or fragment thereof.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: April 20, 2021
    Assignee: SEEVIX MATERIAL SCIENCES LTD.
    Inventors: Shmulik Ittah, Meni Shimel, Uri Gat
  • Patent number: 10961287
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 30, 2021
    Assignee: Amunix Pharmaceuticals, Inc
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • Patent number: 10921330
    Abstract: CSF diagnostic in vitro method for the diagnosis of dementias and neuroinflammatory diseases, in which a determination of the procalcitonin immunoreactivity (PCT immunoreactivity) is carried out in a sample of cerebrospinal fluid (CSF) of a patient who is suffering from a dementia or neuroinflammatory disease or is suspected of suffering from such a disease. Conclusions about the presence, the course, the severity or the success of a treatment of the dementia or neuroinflammatory disease are drawn from a measured PCT immunoreactivity which is above a threshold value typical for healthy individuals.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 16, 2021
    Assignee: B.R.A.H.M.S GMBH
    Inventors: Andreas Bergmann, Andrea Sparwaβer, Harald Hampel
  • Patent number: 10907173
    Abstract: Compositions having pesticidal activity and methods for their use are provided. Compositions include isolated and recombinant polypeptide sequences having pesticidal activity, recombinant and synthetic nucleic acid molecules encoding the pesticidal polypeptides, DNA constructs comprising the nucleic acid molecules, vectors comprising the nucleic acid molecules, host cells comprising the vectors, and antibodies to the pesticidal polypeptides. Nucleotide sequences encoding the polypeptides provided herein can be used in DNA constructs or expression cassettes for transformation and expression in organisms of interest. The compositions and methods provided herein are useful for the production of organisms with enhanced pest resistance or tolerance. Transgenic plants and seeds comprising a nucleotide sequence that encodes a pesticidal protein of the invention are also provided. Methods are provided for producing the polypeptides disclosed herein, and for using those polypeptides for controlling a pest.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: February 2, 2021
    Assignee: AgBiome, Inc.
    Inventors: Kira Bulazel Roberts, Rebecca E. Thayer, Jessica Parks
  • Patent number: 10907219
    Abstract: This disclosure describes compositions and methods that involve a first modular component and a second modular component. The first modular component includes a first target molecule coupled to a first dimerizing moiety. The second modular component includes a second target molecule coupled to a second dimerizing moiety. The first dimerizing moiety dimerizes with the second dimerizing moiety when the first dimerizing moiety binds a chemical induced proximity (CIP) inducer.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: February 2, 2021
    Assignee: UNM Rainforest Innovations
    Inventors: Fu-Sen Liang, Wei Wang
  • Patent number: 10900968
    Abstract: A method of prognosing and predicting breast cancer recurrence stratifies early stage ER+/PR+ and Her2? breast cancer patients with invasive ductal/lobular carcinoma of the breast into low risk or high risk for breast cancer recurrence by employing an IHC based assay which assesses or measures expression of a combination of 5 biomarkers and by employing a histopathological analysis which assesses 3 clinical prognostic parameters.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: January 26, 2021
    Assignee: ONCOSTEM PTE. LTD.
    Inventors: Manjiri Bakre, Charusheila Ramkumar
  • Patent number: 10888609
    Abstract: The present invention provides in certain embodiments compositions comprising at least one CD200 inhibitor, and methods of reversing or modulating immune suppression in a patient having a disease or disorder arising from abnormal cell growth, function or behavior, which method comprises administering to a patient in need thereof a CD200 inhibitor composition.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 12, 2021
    Assignee: Regents of the University of Minnesota
    Inventor: Michael Olin
  • Patent number: 10870925
    Abstract: Protein arrays and their use to assay, in a parallel fashion, the protein products of highly homologous or related DNA coding sequences and described. By highly homologous or related it is meant those DNA coding sequences which share a common sequence and which differ only by one or more naturally occurring mutations such as single nucleotide polymorphisms, deletions or insertions, or those sequences which are considered to be haplotypes. Such highly homologous or related DNA coding sequences are generally naturally occurring variants of the same gene. Arrays according to the invention have two or more individual proteins deposited in a spatially defined pattern on a surface in a form whereby a property such as an activity or function of the proteins can be investigated or assayed in parallel by interrogation of the array.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: December 22, 2020
    Assignee: SENGENICS CORPORATION PTE LTD
    Inventors: Jonathan Mark Boutell, Benjamin Leslie James Godber, Darren James Hart, Jonathan Michael Blackburn
  • Patent number: 10865233
    Abstract: Methods for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising an NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: December 15, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Glenn Dranoff, Matthew Vanneman, Gordon Freeman
  • Patent number: 10859575
    Abstract: The present invention relates to novel peptides that may be used in whole or in combination for the detection of Mycobacterium tuberculosis infection. In particular, the present invention relates to compositions and methods involving detection of antibodies contained in the blood of non-human primates that arise from an infection from M. tuberculosis or vaccination using an epitope specific inoculation. More particularly, the present invention provides a means to distinguish early, active, and latent M. tuberculosis infection. More particularly, the present invention describes an immunological diagnostic mechanism for the detection of M. tuberculosis infection.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: December 8, 2020
    Assignee: Intuitive Biosciences, Inc.
    Inventor: Kimberly Luke
  • Patent number: 10835585
    Abstract: Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier, each neoantigenic peptide comprising a tumor-specific neoepitope capable of binding to an HLA protein in a subject, each tumor-specific neoepitope comprising a tumor-specific mutation present in a tumor, wherein (a) the composition comprises neoantigenic peptides comprising tumor-specific mutations present in at least 1% of subjects in a population of subjects suffering from cancer; (b) the composition comprises neoantigenic peptides comprising tumor-specific neoepitopes which bind to HLA proteins present in at least 5% of subjects in the population; and (c) the composition comprises at least one neoantigenic peptide capable of eliciting an immune response against a tumor present in at least 5% of the subjects in the population of subjects suffering from cancer.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: November 17, 2020
    Assignees: The Broad Institute, Inc., Dana Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Edward F. Fritsch, Nir Hacohen, Michael S. Rooney, Sachet Ashok Shukla, Catherine J. Wu, Pavan Bachireddy, Jing Sun
  • Patent number: 10822396
    Abstract: The invention provides a method for preparing a super-complex which comprises repeat-chains containing single or multiple kinds of monomer-specific protein binding domains having at least two binding sites for a monomer repeated therein; preparing single complexes of the repeat-chains and a protein monomer having at least two binding sites for the monomer-specific binding domain of the repeat-chains, by mixing the repeat-chains and the protein monomer, and then generating the super-complex by forming cross-binding between the single complexes of repeat-chains and the protein monomers.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: November 3, 2020
    Inventor: MuHyeon Choe
  • Patent number: 10821094
    Abstract: The invention provides methods of treating an allergic inflammatory condition characterized by inflammation of a squamous epithelium in a target tissue using alpha-1 proteinase inhibitors to replenish SPINK7 protein and/or SPINK7 anti-proteinase activity in the target tissue, and related methods and compositions.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: November 3, 2020
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Nurit P. Azouz, Marc E. Rothenberg
  • Patent number: 10815297
    Abstract: The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: October 27, 2020
    Assignees: MORPHOSYS AG, GALAPAGOS NV
    Inventors: Andreas Bültmann, Robert Mühlbacher, Teresa Garcia, Reginald Christophe Xavier Brys, Luc Nelles, Katja Conrath
  • Patent number: 10793900
    Abstract: The present invention discloses a novel polypeptide capable of binding Taq DNA polymerase, a polynucleotide encoding the polypeptide, a recombinant vector comprising the polynucleotide, a cell having the recombinant vector introduced therein, a method of producing the polypeptide using the recombinant cell, and a hot-start PCR composition comprising the polypeptide. The polypeptide of the present invention is capable of binding specifically to Taq DNA polymerase to inhibit the activity of the polymerase, and thus may be effectively used in hot-start PCR using Taq DNA polymerase.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: October 6, 2020
    Assignees: ENZYNOMICS CO. LTD., KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Da-Eun Hwang, Yong Keol Shin, Palinda Ruvan Munashingha, So Yeon Park, Yeon-Soo Seo, Hak-Sung Kim
  • Patent number: 10786560
    Abstract: The present disclosure is based upon the identification of a number of Streptococcus agalactiae genes which are required for virulence in fish species. Specifically, the disclosure relates to genomic content present in fish-associated S. agalactiae strains that is absent from strains which are non-virulent to fish. Further disclosed is the use of a number of S. agalactiae proteins and antigens in methods, immunogenic compositions and vaccines for raising immune responses and treating or preventing diseases, conditions and/or infections with a Streptococcal aetiology.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: September 29, 2020
    Assignee: MOREDUN RESEARCH INSTITUTE
    Inventors: Michael Fontaine, Ruth Nicolet Zadoks, Christian Marie Joseph Delannoy
  • Patent number: 10774123
    Abstract: The present invention provides the CP-BMP recombinant protein with technical advantages as an intracellular protein therapy for the treatment of bone defects caused by osteogenesis imperfecta, osteoporosis, fracture and osteoctomy in that it could resolve cell-/tissue-permeability and bio-transfer function.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: September 15, 2020
    Assignee: CELLIVERY THERAPEUTICS, INC.
    Inventor: Daewoong Jo
  • Patent number: 10766933
    Abstract: The present invention relates to a mutated immunoglobulin-binding protein having increased alkaline tolerance and, more specifically, to an immunoglobulin-binding protein in which, with respect to the A-domain of Staphylococcal protein A, or a functional variant thereof, an amino acid at a specific site is mutated and thereby exhibits an increased chemical stability at an alkaline pH value in comparison to a parental molecule. The present invention can provide an antibody-purifying immunoglobulin-binding protein ligand and matrix which have enhanced alkaline tolerance and accordingly enhanced stability in multiple times of alkaline cleaning.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: September 8, 2020
    Assignee: Amicogen, Inc.
    Inventors: Yong Chul Shin, Zhe Piao, Su-Lim Choi, Yang Ho Jo, So-Young Park, Dae Beom Kwon
  • Patent number: 10752670
    Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a GD3 monoclonal antibody, conferring specific immunity against GD3 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating solid tumors such as melanomas, carcinomas or liquid tumor such as T-cell lymphoblastic leukemia.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: August 25, 2020
    Assignee: CELLECTIS
    Inventors: Julianne Smith, Cècile Schiffer-Mannioui
  • Patent number: 10731176
    Abstract: DIG-305 insecticidal protein toxins, polynucleotides encoding such toxins, and transgenic plants that produce such toxins are disclosed. Also disclosed are methods for using such toxins to control insect pests in plants, especial crop plants. Methods for preparing transgenic plants expressing the protein toxins and methods for detecting the claimed toxins and polynucleotides in transgenic plants are disclosed.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: August 4, 2020
    Assignee: DOW AGROSCIENCES LLC
    Inventors: Timothy D. Hey, Meghan L. F. Frey, Xiaoping Xu, Audrey Jane Etter, Elizabeth Caldwell, Ted Letherer, Navin Elango, Kenneth Narva
  • Patent number: 10722587
    Abstract: The present invention relates to a composition for intracellular delivery containing an adenovirus protein VI-derived peptide and an anti-cancer pharmaceutical composition containing the same. According to the present invention, the use of the peptide or peptide-polymer composite of the present invention improves intracellular delivery efficiency of a nucleic acid, a peptide, a poly-peptide, an antibody, a chemical material, or a virus. Therefore, the peptide or peptide-polymer composite of the present invention can be favorably used as an intracellular delivery system for various therapeutics.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: July 28, 2020
    Assignee: GENEMEDICINE CO., LTD.
    Inventor: Chae Ok Yun
  • Patent number: 10703812
    Abstract: The present invention relates to a receptor-binding domain of an IgE-dependent histamine releasing factor (HRF), and a use thereof, and more specifically, ascertains, as an HRF structural region, and a FL domain and an H2 domain which bind to a receptor of HRF existing in a cell membrane, ascertains the C-terminus domain of the HRF, and ascertains that a material binding thereto inhibits IL-8 secretion, thereby determining that the FL and H2 domains and the C-terminus domain can be utilized in: the development of a therapeutic agent for treatment and prevention of HRF-related disease including allergic diseases such as asthma, bronchitis, chronic obstructive pulmonary disease, bronchiectasis, rhinitis, atopic dermatitis, hives (urticaria), hay fever, conjunctivitis, and anaphylaxis; inflammatory diseases such as bronchitis, pneumonia, arthritis, nephritis, psoriasis, dermatitis, Crohn's disease, enteritis, gingivitis, arteriosclerosis, coronary arteritis, hepatitis, Behcet's disease, bladder cancer, prostatit
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: July 7, 2020
    Assignee: EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION
    Inventors: Kyunglim Lee, Dong Hae Shin, Mi-Sun Kim, Mi Young Kim, Jeehye Maeng, Hee-Won Lee
  • Patent number: 10689423
    Abstract: Provided herein are recombinant CTLA-4 binding proteins, which are, inter alia, useful for the treatment of cancer. The recombinant proteins provided herein are, inter alia, capable of binding CTLA-4 proteins on a tumor cell. In a first aspect, there is provided a recombinant CTLA-4 binding protein including (i) a CTLA-4 binding domain; (ii) a CTLA-4 binding domain masking peptide; and (iii) a cleavable peptide linker connecting the CTLA-4 binding domain masking peptide to the CTLA-4 binding domain. In another aspect, there is provided a dimerizing domain covalently attached to the CTLA-4 binding domain, wherein the binding protein domains are bound together.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: June 23, 2020
    Assignees: City of Hope, Thomas Jefferson University and Health System Innovation Pillar
    Inventors: John Williams, Ulrich Rodeck
  • Patent number: 10682399
    Abstract: A set of target peptides are presented by HLA A*0201, B*0301, B*0702 and B*2705 on the surface of disease cells. They are envisioned to, among other things, stimulate an immune response to the proliferative disease, e.g., colorectal cancer, to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, facilitate antibody recognition of tumor boundaries in surgical pathology samples, act as biomarkers for early detection and/or diagnosis of the disease, and/or act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: June 16, 2020
    Assignees: The University of Birmingham, University of Virginia Patent Foundation
    Inventors: Donald F. Hunt, Jeffrey Shabanowitz, Jennifer G. Abelin, Mark Cobbold, Sarah Amy Penny
  • Patent number: 10677794
    Abstract: The present invention relates to compositions and methods for visualizing disease-specific T-cells. In particular, the present invention relates to compositions and methods for use in the diagnosis, monitoring of progression, monitoring of response to therapy, and selection of patients for therapy of autoimmune diseases characterized by selective expansion of disease-specific effector memory T-cells.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: June 9, 2020
    Assignee: OSLO UNIVERSITETSSYKEHUS HF
    Inventors: Ludvig Sollid, Shuo-wang Qiao, Asbjorn Christophersen, Knut E. A. Lundin
  • Patent number: 10670600
    Abstract: The invention relates to isolated peptides and chimeric polypeptides derived from Saposin A that have anti-angiogenic activity. These peptides are small, consisting essentially of at least 10 consecutive amino acid residues from the 31st-50th amino acid residue of Saposin A. The invention also relates to the use of these isolated peptides and chimeric polypeptides in compositions for the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: June 2, 2020
    Assignee: Children's Medical Center Corporation
    Inventor: Randolph Watnick
  • Patent number: 10669316
    Abstract: The present invention relates to compositions comprising improved flagellin derived constructs and methods of using the same in the treatment of various diseases.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: June 2, 2020
    Assignee: Genome Protection, Inc.
    Inventor: Vadim Mett
  • Patent number: 10669345
    Abstract: A cell-permeable polypeptide includes a membrane transduction domain and a polypeptide comprising an amino acid sequence substantially homologous to the amino acid sequence of the TRAF2,3 binding domain, the cell permeable peptide inhibiting binding of TRAF2 to the TRAF2,3 binding domain of CD40 to decrease or inhibit a CD-40 activity or signal transduction pathway associated with a CD40-mediated disease in cells of a subject.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: June 2, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Carlos Subauste, Cecilia Subauste
  • Patent number: 10660948
    Abstract: The present disclosure relates to fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more tumor specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more viral specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins. It also relates to methods to activate the immune system in cancer patients to infiltrate and kill tumor cells or cells infected with a latent virus. The present disclosure provides a platform technology that elicits a faster, broader and stronger immune response using the fusion proteins.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 26, 2020
    Assignee: OMNICYTE
    Inventors: Peter Leonardi, Elin Martina Pola, Jeffrey Babad
  • Patent number: 10663475
    Abstract: Disclosed herein are methods and compositions for identifying and/or treating subjects having or likely to have amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). Antibodies specific for one or more di-amino acid repeat-containing proteins are also provided herein.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: May 26, 2020
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Laura Ranum, Tao Zu
  • Patent number: 10654934
    Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: May 19, 2020
    Assignee: Innovative Cellular Therapeutics Co., Ltd.
    Inventors: Lei Xiao, Zhao Wu, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi
  • Patent number: 10646347
    Abstract: Osteoconductive synthetic bone grafts are provided in which porous metallic matrices are loaded with an osteoinductive protein. In certain embodiments, the grafts include porous ceramic granules deposited within the matrices.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: May 12, 2020
    Assignee: Bioventus LLC.
    Inventors: Jeffrey Welch, Eric Vanderploeg, Christopher Wilson, John Wozney
  • Patent number: 10648014
    Abstract: Disclosed are compositions and methods for measuring tyrosine kinase activity using degradation resistant biosensors comprising a reporter sequence, a target sequence, and a transduction sequence. In certain embodiments, the invention includes a biosensor comprising a peptide comprising a reporter sequence, i.e., an amino acid sequence including a tyrosine residue that can be phosphorylated by a tyrosine kinase. In certain embodiments, a biosensor comprises a reporter sequence configured to resist degradation from proteases, a targeting sequence coupled to the reporter sequence and configured to bind to a protein interaction domain of a kinase, and a transduction sequence coupled to the targeting sequence.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: May 12, 2020
    Assignee: Purdue Research Foundation
    Inventors: Laurie L Parker, Robert John Schuster
  • Patent number: 10646542
    Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: May 12, 2020
    Assignee: Molecular Partners AG
    Inventors: Hans Kaspar Binz, Patrik Forrer, Michael Tobias Stumpp
  • Patent number: 10647997
    Abstract: A modified effector cell includes a non-reversibly produced vector-encoded anti-GD2-BB-? chimeric receptor for use in disialoganglioside GD2-expressing neoplasia, which is inserted in the cell, to obtain an effector cell that stably produces the anti-GD2-BB-? chimeric receptor, the chimeric receptor having two distinct mutually fused portions, i.e. an intra-cytoplasmic portion and an extra-cytoplasmic portion.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: May 12, 2020
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: Massimo Dominici, Sara Caldrer, Maria Carlotta Spano, Paolo Paolucci, Marco Bestagno, Dario Campana
  • Patent number: 10633712
    Abstract: The technology described herein relates to assays and methods for the diagnosis, prognosis, and/or treatment of melanoma, e.g. relating to measuring the level of neurophilin-2 (NRP-2) mRNA expressed in melanoma cells. In some embodiments, the level of NRP-2 can be normalized to the level of Melan-A (MART) mRNA.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: April 28, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Rhoda M. Alani, Byungwoo Ryu
  • Patent number: 10626184
    Abstract: In various embodiments the invention provides anti-mucin-like protein (MLP) monoclonal antibodies, compositions and methods for detecting MLP as a biomarker for mucin-secreting type of cancer such as ovarian or pancreatic cancer.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: April 21, 2020
    Assignees: Omeros Corporation, University of Leicester
    Inventors: Hans-Wilhelm Schwaeble, Gregory A. Demopulos
  • Patent number: 10611809
    Abstract: A single-domain antibody (sdAb) is produced by causing a bacteria to express the sdAb into cytoplasm of the bacteria, wherein the sdAb is expressed as a fusion protein with the acid tail of ?-synuclein. In embodiments, the protein is free of a periplasmic location tag. Such antibodies have the unexpected ability to refold after thermal denaturation.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: April 7, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Daniel Zabetakis, George P. Anderson, Ellen R. Goldman, Kendrick Turner, P. Audrey Brozozog Lee
  • Patent number: 10576145
    Abstract: The present invention provides in certain embodiments conjugates comprising at least one CD200 inhibitor and an adjuvant, and methods of reversing or modulating immune suppression in a patient having a disease or disorder arising from abnormal cell growth, function or behavior, which method comprises administering to a patient in need thereof a composition comprising a CD200 inhibitor and an adjuvant.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: March 3, 2020
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventor: Michael Olin
  • Patent number: 10577401
    Abstract: A nucleic acid encodes a single-domain antibody (sdAb) is produced by causing a bacteria to express the sdAb into cytoplasm of the bacteria, wherein the sdAb is expressed as a fusion protein with the acid tail of ?-synuclein. In embodiments, the protein is free of a periplasmic location tag. Such antibodies have the unexpected ability to refold after thermal denaturation.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: March 3, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Daniel Zabetakis, George P. Anderson, Ellen R. Goldman, Kendrick Turner, P. Audrey Brozozog Lee
  • Patent number: 10563179
    Abstract: The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: February 18, 2020
    Assignee: University of Washington Through Its Center for Commercialization
    Inventors: Edward Clark, Jay Wesley Chaplin
  • Patent number: 10562966
    Abstract: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: February 18, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: David Paul Humphreys, Shirley Jane Peters, Ralph Adams, James Heads
  • Patent number: 10561705
    Abstract: A peptide comprising SEQ ID NO: 1 (Xaa1-Tyr-Phe-Ala-Tyr-His-Pro-Asn-Ile-Pro-Gly-Leu-Xaa2-Tyr-Phe), wherein Xaa1 is any one selected from the group consisting of tyrosine, tryptophan, phenylalanine and non-natural amino acids having characteristics identical to tyrosine, tryptophan or phenylalanine; and Xaa2 is any one selected from the group consisting of tyrosine, tryptophan, phenylalanine, and non-natural amino acids having the characteristics identical to tyrosine, tryptophan or phenylanine is described.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: February 18, 2020
    Inventor: Brian Byeoung Kim
  • Patent number: 10548895
    Abstract: The invention pertains to ligands that bind to CD81 and that inhibit or block Plasmodium attachment to CD81, compositions and methods for preventing, inhibiting or treating infection by Plasmodium and ligands that target a Plasmodium binding site on CD81 and methods of making and using them. A series of ligand binding sites on the large extracellular loop of the open conformation of CD81 have been identified. Several important sites were located in regions identified by mutational studies to be the site of Plasmodium binding. Ligands that recognize these sites were identified. Linking together two or three ligands that bind with low or moderate affinities to different structurally unique sites on a target protein were used to generate small molecule ligand conjugates that exhibit very high affinities to their CD81 targets. Hybrid ligand molecules were also designed using fragment-based drug design methods to generate analogs of the ligands that bind more tightly to the protein than the parent compounds.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: February 4, 2020
    Assignee: The American University in Cairo
    Inventors: Hassan Azzazy, Reem Al-Olaby, Rodney Balhorn
  • Patent number: 10538575
    Abstract: There are described herein novel soluble IGF receptor Fc fusion proteins and compositions and methods of use thereof for treating angiogenesis associated disorders and malignant disease, such as cancer and metastasis, wherein the fusion proteins bind specifically to IGF-1 or IGF-2.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: January 21, 2020
    Inventors: Pnina Brodt, Bernard Massie, Traian Sulea
  • Patent number: 10538587
    Abstract: The present disclosure relates to antibodies or fragments thereof that target at least one conformational epitope of a Notch 3 or mutant Notch 3 receptor; and compositions and methods of use thereof.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: January 21, 2020
    Assignee: Novartis AG
    Inventors: Joelle Deplazes-Lauber, Christy Fryer, Tiacen Hu, David Jenkins, Konstantin Petropoulos, Philippe Thiel
  • Patent number: 10533161
    Abstract: A NADPH oxidase (Nox) protein includes a domain including 3 to 7 transmembrane helices, and an amino acid sequence including at least 2 bis-histidyl motifs, wherein each of the bis-histidyl motifs consists of 2 histidine residues separated by 12, 13 or 14 amino acid residues. The Nox protein may be produced by a method that includes solubilizing a solution of cells expressing the Nox protein using a detergent from the maltoside family to suspend the Nox protein in the solution.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: January 14, 2020
    Assignees: UNIVERSITE GRENOBLE ALPES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jérôme Dupuy, Christine Hajjar, Mickaël Cherrier, Franck Fieschi
  • Patent number: 10524473
    Abstract: Disclosed are peptides that induce an active plant response, but not a hypersensitive response, when applied to plant tissue. These peptides also preferably exhibit improved solubility, stability, resistance to chemical degradation, or a combination of these properties. Use of these peptides or fusion polypeptides, or DNA constructs encoding the same, for modulating plant biochemical signaling, imparting disease resistance to plants, enhancing plant growth, imparting tolerance to biotic stress, imparting tolerance and resistance to abiotic stress, imparting desiccation resistance to cuttings removed from ornamental plants, imparting post-harvest disease or post-harvest desiccation resistance to a fruit or vegetable, or enhancing the longevity of fruit or vegetable ripeness are also disclosed.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: January 7, 2020
    Assignee: Plant Health Care, Inc.
    Inventors: Zhongmin Wei, Gregory A. Zornetzer